Table 3.
Individual analysis of protein and gene expression profile and survival
| Parameter |
Univariate relapse-free HR (95% CI) | Adjusted relapse-free HR (95% CI) | Univariate overall survival HR (95% CI) | Adjusted overall survival HR (95% CI) | |
| ≤9 nodes, not inflammatory | 1 (baseline) | 1 (baseline) | 1 (baseline) | 1 (baseline) | |
| >9 nodes, not inflammatoryb | 1.52 (0.81–2.85) | 1.65 (0.85–3.22) | 1.44 (0.69–3.03) | 1.55 (0.70–3.44) | |
| Inflammatory breast cancer | 1.78 (0.87–3.63) | 1.68 (0.79–3.56) | 2.07 (0.91–4.67) | 1.88 (0.79–4.49) | |
| Stage II | 1 (baseline) | 1 (baseline) | 1 (baseline) | 1 (baseline) | |
| Stage IIIA | 1.36 (0.92–2.03) | 1.40 (0.91–2.13) | 1.49 (0.93–2.40) | 1.56 (0.94–2.60) | |
| Stage IIIB | 1.44 (0.88–2.35) | 1.43 (0.85–2.40) | 1.84 (1.06–3.20)a | 1.85 (1.03–3.33)a | |
| Inflammatory (all 3B) | 1.24 (0.79–1.93) | 1.23 (0.77–1.96) | 1.51 (0.92–2.45) | 1.47 (0.87–2.43) | |
| Inflammatory (exclude 3B noninflammatory)b | 1.29 (0.82–2.01) | 1.20 (0.76–1.91) | 1.56 (0.96–2.54) | 1.50 (0.89–2.48) | |
| High grade | 1.47 (1.01–2.13)a | 1.23 (0.83–1.83) | 1.70 (1.09–2.63) | 1.31 (0.82–2.09) | |
| Nodes (continuous) | 1.03 (1.01–1.06)a | 1.04 (1.01–1.06)a | 1.03 (1.01–1.06)a | 1.04 (1.01–1.07)a | |
| Immunohistochemistry | |||||
| KI-67 | High | 1.58 (1.00–2.51) | 1.23 (0.73–2.08) | 1.73 (1.03–2.90)a | 1.20 (0.67–2.16) |
| p53 | Low | 0.65 (0.43–0.98)a | 0.80 (0.50–1.26) | 0.54 (0.34–0.86)a | 0.68 (0.41–1.12) |
| ER/PR | + | 0.57 (0.40–0.81)a | 0.59 (0.40–0.87)a | 0.49 (0.32–0.73)a | 0.54 (0.34–0.84)a |
| HER2 | 2/3+ | 1.40 (0.95–2.06) | 1.29 (0.86–1.94) | 1.69 (1.08–2.64)a | 1.77 (1.11–2.83)a |
| EGFR | 3+ | 1.55 (1.00–2.40) | 1.38 (0.87–2.19) | 1.66 (1.02–2.73)a | 1.46 (0.87–2.45) |
| MAPK | 3+ | 0.66 (0.39–1.12) | 0.62 (0.36–1.08) | 0.48 (0.25–0.94)a | 0.44 (0.22–0.89)a |
| p27 | 0 | 1.85 (1.25–2.72)a | 2.04 (1.37–3.04)a | 2.26 (1.45–3.51)a | 2.44 (1.55–3.83)a |
| p21 | Low (0) | 1.77 (1.21–2.61)a | 1.70 (1.15–2.53)a | 1.93 (1.23–3.04)a | 1.96 (1.23–3.10)a |
| p16 | High | 1.99 (1.30–3.05)a | 1.73 (1.06–2.83)a | 1.85 (1.13–3.02)a | 1.44 (0.82–2.52) |
| Gene expression by RT-PCR | |||||
| p21 | Low | 1.66 (1.09–2.54)a | 1.20 (0.76–1.90) | 1.83 (1.13–2.94)a | 1.33 (0.79–2.22) |
| EGFR | High | 2.78 (1.53–5.04)a | 2.73 (1.41–5.26)a | 2.59 (1.36–4.93)a | 2.16 (1.07–4.37)a |
| HER2 | High | 1.31 (0.84–2.04) | 1.14 (0.72–1.81) | 1.33 (0.81–2.17) | 1.15 (0.67–1.96) |
| β-tubulin | High | 1.15 (0.69–1.92) | 1.02 (0.60–1.74) | 1.11 (0.62–1.99) | 1.00 (0.55–1.82) |
| COX2 | High | 0.99 (0.53–1.85) | 0.91 (0.47–1.75) | 0.64 (0.33–1.26) | 0.57 (0.28–1.18) |
| Cyclin-E | High | 1.24 (0.71–2.15) | 0.89 (0.47–1.67) | 1.52 (0.83–2.77) | 1.17 (0.59–2.33) |
| ERCC1 | Low | 1.57 (1.03–2.39)a | 1.27 (0.80–2.01) | 1.53 (0.95–2.47) | 1.18 (0.70–1.99) |
| GST-P1 | High | 1.54 (1.00–2.38) | 1.22 (0.76–1.94) | 1.43 (0.87–2.36) | 1.16 (0.68–1.99) |
| MDR1 | Low | 1.42 (0.77–2.60) | 1.47 (0.77–2.80) | 1.80 (0.90–3.60) | 2.11 (1.00–4.45)a |
a
P < 0.05. Adjusted for grade, nodes (continuous), ER/PR+, age, and inflammatory.
b
Excluding single patient with noninflammatory stage IIIB impacted hazard ratio (HR) of genes and proteins by <1% and did not alter statistical significance.